公司資料
10x Genomics 股價、新聞與催化劑
- 股票代碼:
- TXG
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
88.76 USD (-1.77%)
收盤價
最後更新: 2026年10月1日
3.9B USD
市值
股價為何變動
截至 2026年10月1日，TXG 下跌 1.77%，收於 $88.76。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Single-Cell and Spatial Biology Company
10x Genomics develops instruments, consumables, software, and analysis tools that allow researchers to measure biological systems at single-cell and spatial resolution. Its platforms are used across academic research, translational medicine, biopharma discovery, and emerging diagnostic applications.
Chromium Single-Cell Platform
The Chromium platform partitions cells and biological molecules for high-throughput analysis of gene expression, immune repertoires, chromatin accessibility, and multiomic features. Instrument placements support recurring sales of proprietary chips, reagents, and workflow consumables.
Visium Spatial Profiling
Visium products measure gene expression while preserving tissue location, allowing researchers to connect molecular signals with histology and tissue architecture. The platform supports discovery across oncology, neuroscience, immunology, developmental biology, and pathology research.
Xenium In Situ Analysis
Xenium performs targeted, high-plex RNA analysis directly within tissue sections at subcellular resolution. It complements Visium by enabling researchers to study selected gene panels with detailed spatial localization and cell-level morphology.
Next-Generation Platforms and Software
Atera is designed to expand the scale and flexibility of spatial biology, while the acquisition of Proteintech Genomics adds antibody-based protein measurement capabilities. 10x Genomics is also investing in software and computational tools that convert large single-cell and spatial datasets into interpretable biological conclusions.
未來催化劑
- Global commercial shipments of the Atera spatial biology platform in the second half of 2026.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。